BioEclosion SL aims to become the new gold standard for early detection of diseases affecting global health by means of the next generation of rapid diagnostic test using a novel medical device. BioEclosion SL was founded as a spin-off of the Universitat Autònoma de Barcelona (UAB) in 2016. Since then, BioEclosion SL has developed a magnetic IVD which improves the current state-of-art by easing the test performance with a quick, easy to read, one-time use and reliable cartridge embracing the ASSURED guidelines for point-of-need devices.

Main tasks in the project

BioEclosion owns the core technology for the non-invasive IVD to detect both biomarkers at point-of-care.